Overview

Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar Depression

Status:
Completed

Trial end date:
2012-11-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the superior efficacy of quetiapine extended release(XR) mono-therapy, administered once daily compared to placebo, in the treatment of depressive symptoms in patients with Bipolar I and Bipolar II Disorder

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Quetiapine Fumarate